Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F. Saba, Christine H. Chung, Ashley A. McCook‐Veal et al.|Nature Medicine|2023Cited by 76
Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaC. Shen, Ammar Sukari, William Stokes et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1